Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06382051
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-24
First Post:
2024-04-19
Brief Title:
Modifying PEST for Psoriatic Arthritis Screening
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Multicenter Prospective Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool PEST on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ScreenX
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ScreenX
Brief Summary:
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada
Patients will be enrolled in the study for up to 66 days and will be asked to fill-out a PsA screening questionnaire at their first dermatologist visit Patients screening positive for PsA will have a second visit with a rheumatologist where a full PsA diagnosis assessment will be performed A remote end of study EOS visit will be conducted by the dermatologist to document the patients biologic Disease-Modifying Antirheumatic Drugs bDMARDs treatment choice and status
Patients will be enrolled in the study for up to 66 days and will be asked to fill-out a PsA screening questionnaire at their first dermatologist visit Patients screening positive for PsA will have a second visit with a rheumatologist where a full PsA diagnosis assessment will be performed A remote end of study EOS visit will be conducted by the dermatologist to document the patients biologic Disease-Modifying Antirheumatic Drugs bDMARDs treatment choice and status
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None